{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T04:34:28Z","timestamp":1725510868362},"reference-count":16,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1097\/hs9.0000000000000665","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T15:00:07Z","timestamp":1637161207000},"page":"e665","source":"Crossref","is-referenced-by-count":1,"title":["De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment"],"prefix":"10.1002","volume":"5","author":[{"given":"Despina","family":"Fotiou","sequence":"first","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrysanthi","family":"Skalioti","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology and Renal Transplantation, National and Kapodistrian University of Athens, School of Medicine, Laiko Hospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Liapis","sequence":"additional","affiliation":[{"name":"Department of Pathology, National and Kapodistrian University of Athens, School of Medicine, Laiko Hospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smaragdi","family":"Marinaki","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology and Renal Transplantation, National and Kapodistrian University of Athens, School of Medicine, Laiko Hospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,12]]},"reference":[{"key":"R1-20231201","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis.","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"key":"R2-20231201","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1600-6143.2010.03418.x","article-title":"De novo AL amyloidosis in the kidney allograft.","volume":"11","author":"Qian","year":"2011","journal-title":"Am J Transplant"},{"key":"R3-20231201","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000013308","article-title":"De novo AL amyloid in a renal allograft.","volume":"18","author":"Le","year":"1998","journal-title":"Am J Nephrol"},{"key":"R4-20231201","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41408-018-0086-3","article-title":"Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.","volume":"8","author":"Kastritis","year":"2018","journal-title":"Blood Cancer J"},{"key":"R5-20231201","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"R6-20231201","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"R7-20231201","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"R8-20231201","first-page":"1","article-title":"Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis.","volume":"28","author":"Kastritis","year":"2020","journal-title":"Amyloid"},{"key":"R9-20231201","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis.","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"R10-20231201","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","article-title":"Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples.","volume":"95","author":"Dasari","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"R11-20231201","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-021-00428-0","article-title":"Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.","volume":"11","author":"Palladini","year":"2021","journal-title":"Blood Cancer J"},{"key":"R12-20231201","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","article-title":"Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.","volume":"86","author":"Everly","year":"2008","journal-title":"Transplantation"},{"key":"R13-20231201","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.3324\/haematol.2019.231860","article-title":"Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients.","volume":"105","author":"Frerichs","year":"2020","journal-title":"Haematologica"},{"key":"R14-20231201","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"R15-20231201","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-139236","article-title":"T cell immunoprofiling of patients with relapsed and\/or refractory myeloma who receive daratumumab monotherapy: longitudinal analysis during 7 cycle follow-up of the rebuild phase 2 study.","volume":"136","author":"Vlachonikola","year":"2020","journal-title":"Blood"},{"key":"R16-20231201","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/TP.0000000000003247","article-title":"CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection.","volume":"105","author":"Doberer","year":"2021","journal-title":"Transplantation"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T18:04:53Z","timestamp":1702922693000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":16,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/hs9.0000000000000665","relation":{},"ISSN":["2572-9241"],"issn-type":[{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]}}}